Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

被引：0
|
作者：
Dan Liu
Jian Li
Jing Gao
Yanyan Li
Rui Yang
Lin Shen
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology
来源：
BMC Cancer | / 17卷
关键词：
Irinotecan; polymorphisms; polymorphisms; Metastatic colorectal cancer; Toxicity; Clinical response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 30 条
  • [21] UGT1As polymorphisms predict toxicity in colorectal cancer patients treated with different recommended doses of irinotecan oriented by UGT1A1*28 polymorphism based on previous phase I study
    Hazama, S.
    Koudo, H.
    Yoshida, S.
    Shimizu, R.
    Ozasa, H.
    Yamamoto, T.
    Araki, A.
    Yoshino, S.
    Okayama, N.
    Hinoda, Y.
    Oka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis
    Zhu, Xiaoyun
    Ma, Ruchao
    Ma, Xin
    Yang, Gang
    BIOSCIENCE REPORTS, 2020, 40
  • [23] Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
    Xun Cai
    Weiguo Cao
    Honghua Ding
    Tianshu Liu
    Xinli Zhou
    Mei Wang
    Ming Zhong
    Ziyi Zhao
    Qing Xu
    Liwei Wang
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1579 - 1589
  • [24] Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
    Cai, Xun
    Cao, Weiguo
    Ding, Honghua
    Liu, Tianshu
    Zhou, Xinli
    Wang, Mei
    Zhong, Ming
    Zhao, Ziyi
    Xu, Qing
    Wang, Liwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (09) : 1579 - 1589
  • [25] Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review
    Miarons, Marta
    Riera, Pau
    Garcia-Gil, Sara
    Gutierrez-Nicolas, Fernando
    FARMACIA HOSPITALARIA, 2022, 46 (04) : 224 - 233
  • [26] Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
    Ren, Tianshu
    Wang, Shu
    Shen, Zexu
    Xu, Chang
    Zhang, Yingshi
    Hui, Fuhai
    Qi, Xingshun
    Zhao, Qingchun
    DRUG SAFETY, 2021, 44 (01) : 29 - 40
  • [27] Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
    Tianshu Ren
    Shu Wang
    Zexu Shen
    Chang Xu
    Yingshi Zhang
    Fuhai Hui
    Xingshun Qi
    Qingchun Zhao
    Drug Safety, 2021, 44 : 29 - 40
  • [28] Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective
    Paly, Victoria Federico
    Li, Shujun
    Khanduri, Pratishtha
    Asfaw, Alemseged Ayele
    Zou, Denise
    Hernandez, Luis
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1076 - 1085
  • [29] Analysis of UGT1A's polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer
    Tanioka, Hiroaki
    Suzuki, Nobuaki
    Hazama, Shoichi
    Nagasaka, Takeshi
    Iwamoto, Yasuo
    Negoro, Yuji
    Nakagami, Yuki
    Tsunedomi, Ryouichi
    Nagano, Hiroaki
    Okajima, Masazumi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [30] BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT
    Osterlund, P.
    Alonso-Orduna, V.
    Schlichting, C.
    Andre, T.
    Sastre, J.
    Greil, R.
    Kubicka, S.
    Reyes-Rivera, I.
    McCall, B.
    Van Cutsem, E. J. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 195 - 195
123